In the past week the Relief Therapeutics Holding SA (OTCMKTS:RLFTF) stock has had a pretty forgettable time in the market and has declined by as much as 10% amidst a selloff.
However, at the same time, it cannot be denied that a correction in a stock can often be an opportunity as well and hence, it might be a good idea to figure that out. Yesterday, the company along with its collaboration partner Acer Therapeutics Inc announced that the United States Food and Drug Administration had accepted the filing of the New Drug Application for the product ACER 001.
In addition to that, it should also be noted that the FDA also provided a target action date for Prescription Drug User Fee Act of June 5 next year. The New Drug Application with regards to ACER 001 was actually qualified by a pair of bioequivalence trials.
The founder and Chief Executive Officer of Acer Therapeutics, Chris Schelling spoke about the matter as well. He stated that with the start of a review process of its New Drug Application by the FDA, the product takes another progressive step towards hitting the market and being an option for patients who might be suffering from Urea Cycle Disorders.
